Tavaborole是由Anacor Pharmaceuticals公司研发的一种治疗指(趾)甲真菌病的局部抗真菌新药,FDA于2014年7月7日批准其上市[1],商品名为Kerydin(43.5 mg·m L-1的tavaborole溶液)。该药为首个获FDA批准的氧硼杂戊环类抗真菌药,用于红色毛癣菌、须癣毛癣菌等引起的指(趾)甲真菌病(即灰指甲)。Tavaborole的中文化学名称:5-氟-1,3-二氢-2,1-苯并氧杂硼-1-醇;英文化学名称:5-fluoro-1,3-dihydro-2,1- Tavaborole, a topical antifungal drug developed by Anacor Pharmaceuticals for the treatment of toenail onychomycosis, was approved by the FDA on July 7, 2014, [1] under the tradename Kerydin (43.5 mg · m L- 1 tavaborole solution). The drug is the first FDA approved oxaborole antifungal agent for Onychomycosis rubrum, Trichophyton mentagrophytes and other Onychomycosis (ie onychomycosis). Chinese name for chemical name of Tavaborole: 5-fluoro-1,3-dihydro-2,1-benzoxaborol-1-ol;